INTRODUCTION: Although advancing age is known to influence the formation of thyroid nodules, the precise relationship remains unclear. Furthermore, it is uncertain whether age influences the risk that any thyroid nodule may prove cancerous. AIM: The aim was to determine the impact of patient age on nodule formation, multinodularity, and risk of thyroid malignancy. METHOD: We conducted a prospective cohort analysis of consecutive adults (ages 20-95 y) who presented for evaluation of nodular disease from 1995 to 2011. A total of 6391 patients underwent ultrasound and fine-needle aspiration of 12 115 nodules ≥ 1 cm. Patients were divided into six age groups and compared using sonographic, cytological, and histological endpoints. RESULT: The prevalence of thyroid nodular disease increases with advancing age. The mean number of nodules at presentation increased from 1.5 in the youngest cohort (age, 20-30 y) to 2.2 in the oldest cohort (age, >70 y; P < .001), demonstrating a 1.6% annual increased risk for multinodularity (odds ratio, 1.02; P < .001). In contrast, the risk of malignancy in a newly identified nodule declined with advancing age. Thyroid cancer incidence per patient was 22.9% in the youngest cohort, but 12.6% in the oldest cohort (odds ratio, 0.972; P < .001), demonstrating a 2.2% decrease per year in the relative risk of malignancy between ages 20 and 60 years, which stabilized thereafter. Despite a lower likelihood of malignancy, identified cancers in older patients demonstrated higher risk histological phenotypes. Although nearly all malignancies in younger patients were well-differentiated, older patients were more likely to have higher risk papillary thyroid carcinoma variants, poorly differentiated cancer, or anaplastic carcinoma (P < .001). CONCLUSION: With advancing age, the prevalence of clinically relevant thyroid nodules increases, whereas the risk that such nodules are malignant decreases. Nonetheless, when thyroid cancer is detected in older individuals, a higher-risk histological phenotype is more likely. These data provide insight into the clinical paradox that confronts physicians managing this common illness.
INTRODUCTION: Although advancing age is known to influence the formation of thyroid nodules, the precise relationship remains unclear. Furthermore, it is uncertain whether age influences the risk that any thyroid nodule may prove cancerous. AIM: The aim was to determine the impact of patient age on nodule formation, multinodularity, and risk of thyroid malignancy. METHOD: We conducted a prospective cohort analysis of consecutive adults (ages 20-95 y) who presented for evaluation of nodular disease from 1995 to 2011. A total of 6391 patients underwent ultrasound and fine-needle aspiration of 12 115 nodules ≥ 1 cm. Patients were divided into six age groups and compared using sonographic, cytological, and histological endpoints. RESULT: The prevalence of thyroid nodular disease increases with advancing age. The mean number of nodules at presentation increased from 1.5 in the youngest cohort (age, 20-30 y) to 2.2 in the oldest cohort (age, >70 y; P < .001), demonstrating a 1.6% annual increased risk for multinodularity (odds ratio, 1.02; P < .001). In contrast, the risk of malignancy in a newly identified nodule declined with advancing age. Thyroid cancer incidence per patient was 22.9% in the youngest cohort, but 12.6% in the oldest cohort (odds ratio, 0.972; P < .001), demonstrating a 2.2% decrease per year in the relative risk of malignancy between ages 20 and 60 years, which stabilized thereafter. Despite a lower likelihood of malignancy, identified cancers in older patients demonstrated higher risk histological phenotypes. Although nearly all malignancies in younger patients were well-differentiated, older patients were more likely to have higher risk papillary thyroid carcinoma variants, poorly differentiated cancer, or anaplastic carcinoma (P < .001). CONCLUSION: With advancing age, the prevalence of clinically relevant thyroid nodules increases, whereas the risk that such nodules are malignant decreases. Nonetheless, when thyroid cancer is detected in older individuals, a higher-risk histological phenotype is more likely. These data provide insight into the clinical paradox that confronts physicians managing this common illness.
Authors: Edmund S Cibas; Zubair W Baloch; Giovanni Fellegara; Virginia A LiVolsi; Stephen S Raab; Juan Rosai; James Diggans; Lyssa Friedman; Giulia C Kennedy; Richard T Kloos; Richard B Lanman; Susan J Mandel; Nicole Sindy; David L Steward; Martha A Zeiger; Bryan R Haugen; Erik K Alexander Journal: Ann Intern Med Date: 2013-09-03 Impact factor: 25.391
Authors: David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle Journal: Thyroid Date: 2009-11 Impact factor: 6.568
Authors: Leila Yassa; Edmund S Cibas; Carol B Benson; Mary C Frates; Peter M Doubilet; Atul A Gawande; Francis D Moore; Brian W Kim; Vânia Nosé; Ellen Marqusee; P Reed Larsen; Erik K Alexander Journal: Cancer Date: 2007-12-25 Impact factor: 6.860
Authors: Marcos A S de Oliveira; Michael Campbell; Alaa M Afify; Eric C Huang; James W Chan Journal: Biomed Opt Express Date: 2019-08-05 Impact factor: 3.732
Authors: Sujay Kakarmath; Howard T Heller; Caroline A Alexander; Edmund S Cibas; Jeffrey F Krane; Justine A Barletta; Neal I Lindeman; Mary C Frates; Carol B Benson; Atul A Gawande; Nancy L Cho; Matthew Nehs; Francis D Moore; Ellen Marqusee; Mathew I Kim; P Reed Larsen; Norra Kwong; Trevor E Angell; Erik K Alexander Journal: J Clin Endocrinol Metab Date: 2016-09-30 Impact factor: 5.958